CIGB 55

Drug Profile

CIGB 55

Alternative Names: Anti-IL-15 peptide - CIGB

Latest Information Update: 26 Feb 2016

Price : $50

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Developer Center for Genetic Engineering and Biotechnology; Heber Biotec
  • Class
  • Mechanism of Action Immunosuppressants; Interleukin 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 25 Feb 2016 CIGB has patent protection for CIGB 55 in USA, the EU, Japan, Australia, Canada, China, Russia, Mexico and South Africa prior to February 2016
  • 01 Dec 2014 CIBG 55 is available for licensing as of 01 Dec 2014.
  • 31 Dec 2013 Preclinical trials in Autoimmune disorders in Cuba (unspecified route) (CIGB presentation,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top